Drugs / LY404039
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03106571 | Aug 2017 → Jul 2020 | methamphetamine dependence | University of California, Los Angeles | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT01637142 | Jul 2012 | — | Denovo Biopharma LLC | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-02-11 | Denovo Biopharma LLC | Denovo Biopharma Announces Partnership with Orygen on Phase 2 Study Evaluating DB103 (Pomaglumetad Methionil) in Treating Psychosis denovobiopharma.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY404039 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01637142 ↗ |
| Known as | Pomaglumetad | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03106571 ↗ |
| Action | Activate | “Metabotropic glutamate receptor 3 agonist” CHEMBL375611 ↗1“Metabotropic glutamate receptor 2 agonist” CHEMBL375611 ↗ |
| Modality | Small molecule | — CHEMBL375611 ↗ |
| Route | Intravenous | “Administered IV.” NCT01637142 ↗ |
| Target | GRM2 | “Metabotropic glutamate receptor 2 agonist” CHEMBL375611 ↗ |
| Target | GRM3 | “Metabotropic glutamate receptor 3 agonist” CHEMBL375611 ↗ |